Gilead Sciences, Inc. (SNSE:GILD)

Market Cap	148.51T +29.3%
Revenue (ttm)	27.65T +3.5%
Net Income	8.57T +54.5%
EPS	6,836.49 +55.4%
Shares Out	n/a
PE Ratio	17.33
Forward PE	74.56
Dividend	2,964.91 (2,684.88%)
Ex-Dividend Date	Mar 13, 2026

Volume	n/a
Open	n/a
Previous Close	110.43
Day's Range	n/a
52-Week Range	89.71 - 115.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 7, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 17,000
• Stock Exchange: Santiago Stock Exchange
• Ticker Symbol: GILD

Financial Performance

In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.

Financial numbers in USD